Since reports of myocarditis and pericaritis following the use of a messenger RNA vaccine, the CDC Vaccine Advisory Committee met to review several hundred of those cases. In this Fast Fact, Joe Gastaldo, MD, System Medical Director of Infectious Diseases at OhioHealth tells us the committee found the incidence of myocarditis and pericarditis in approximately 12 cases per 1 million doses of messenger RNA vaccines and have determined that the benefit of being vaccinated far outweighs the risks of myocarditis or pericarditis. Remember, in the early days of the pandemic, COVID was also associated with myocarditis. Statistics show cases of myocarditis is higher with COVID compared to the vaccine.
So here is what we know about potential myocarditis and pericarditis when associated with the vaccine:
- Myocarditis and pericarditis are seen mostly after the second dose of an mRNA vaccine
- They occur mostly in those under the age of 30 years old
- They occur predominantly in men more than women
- The vast majority of people with myocarditis and pericarditis improve with supportive measures
Want to more answers to common COVID-19 questions? Check out our Fast Facts page.